TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04293952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance, Resistance, Aerobic, Cognition Exercises (BRACE)
Description: BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Resistance Exercise (BRE)
Description: this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
Study: NCT02875145

Intervention type: PROCEDURE
Intervention: Cataract surgery
Study: NCT03709108

Intervention type: OTHER
Group type: OTHER
Intervention: SI-Informed Bolus Calculator
Description: The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission

Intervention type: OTHER
Group type: OTHER
Intervention: SI-Informed Bolus Calculator
Description: The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
Study: NCT02634424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPKFiT
Description: Adjustment of the treatment dose using a decision support software according to the PK values
Study: NCT01547624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck specific exercises
Description: Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
Study: NCT00610909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04484389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise brochure
Description: General exercise protocol will be prepared and given to the control group as a brochure
Study: NCT02577003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: 50 mg tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to ipragliflozin tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Background medication; 50 mg tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Background medication; 50 mg tablet administered orally
Study: NCT03210519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus
Description: taken orally once/day for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taken orally once/day for 90 days
Study: NCT04030689

Intervention type: OTHER
Intervention: data collected from patient file
Description: socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
Study: NCT00708851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCD Solution with NB-UVB Phototherapy
Description: LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB Light Device (311-315 nm)
Description: NB-UVB Phototherapy: 3 light exposures / week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB Light Device (311-315 nm)
Description: NB-UVB Phototherapy: 3 light exposures / week
Study: NCT03253432

Intervention type: OTHER
Intervention: Genetic testing
Description: Targeted next-generation sequencing for familial hypercholesterolemia causative mutations

Intervention type: OTHER
Intervention: Genetic testing
Description: Targeted next-generation sequencing for familial hypercholesterolemia causative mutations

Intervention type: OTHER
Intervention: Genetic testing
Description: Targeted next-generation sequencing for familial hypercholesterolemia causative mutations

Intervention type: OTHER
Intervention: Genetic testing
Description: Targeted next-generation sequencing for familial hypercholesterolemia causative mutations

Intervention type: OTHER
Intervention: Genetic testing
Description: Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
Study: NCT00311415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C conjugate vaccine
Description: Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age
Study: NCT00534053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Educational Reminder
Description: 1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
Study: NCT02888223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xyntha

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xyntha
Study: NCT04291209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
Study: NCT00737828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative care pathway guided by CPX results
Description: * AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure
Study: NCT03795662

Intervention type: OTHER
Intervention: No intervention
Description: Obervational
Study: NCT02017626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mCyp c 1
Description: 2 patient groups with different doses of allergen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mCyp c 1
Description: 2 patient groups with different doses of allergen.
Study: NCT00737828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative care pathway guided by CPX results
Description: * AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure
Study: NCT04182113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
Study: NCT03373357

Intervention type: OTHER
Group type: OTHER
Intervention: Patient not SAHOS
Description: Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~* Cardiovascular events arisen during the duration of the study~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients

Intervention type: OTHER
Group type: OTHER
Intervention: Patient SAHOS sailed by the ventilation in PPC and not sailed
Description: Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~* Questionnaire of evaluation of the global quality of life of the SAHOS~* Appearance of new cardiovascular risk factors~* Cardiovascular events arisen during the duration of the study~* Modification of the current treatments~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients
Study: NCT02092649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Study: NCT04182113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
Study: NCT02076815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide retard
Description: Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thromboreductin
Description: Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
Study: NCT04269824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention package
Description: Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior
Study: NCT00031772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Questionnaire and telephone intervention
Study: NCT01962623

Intervention type: OTHER
Group type: OTHER
Intervention: IPT-MBD
Description: IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPT-MBD
Description: IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
Study: NCT02517021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-netupitant/Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant/Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT05624216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-084
Description: Radiofrequency and targeted pressure energy devices for the treatment of cellulite
Study: NCT04114656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
Study: NCT05229627

Intervention type: DRUG
Intervention: MPH
Description: the drug would be prescribed to patients without any contraindication

Intervention type: DRUG
Intervention: MPH
Description: the drug would be prescribed to patients without any contraindication

Intervention type: DRUG
Intervention: ATX
Description: the drug would be prescribed to patients without any contraindication

Intervention type: DRUG
Intervention: ATX
Description: the drug would be prescribed to patients without any contraindication
Study: NCT00768573

Intervention type: DRUG
Intervention: sildenafil
Description: Oral suspension of sildenafil.
Study: NCT02731547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco School-Based Intervention
Study: NCT01905332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Literacy promoting home based program
Description: The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Literacy Toolkit
Description: Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
Study: NCT00550576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digibind (Fab)
Description: Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
Study: NCT02284386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine SNB
Description: SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL Infiltration
Description: Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
Study: NCT00160342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.45 EE
Study: NCT04182113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS Stimulation
Description: rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
Study: NCT02639806

Intervention type: DRUG
Intervention: Sevoflurane

Intervention type: DRUG
Intervention: Lidocaine
Study: NCT02153905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Description: Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Description: Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study: NCT03839810

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stochastic resonance electrical stimulation
Description: stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stochastic resonance electrical stimulation
Description: stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training
Study: NCT03236610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir monotherapy
Description: switching to tenofovir monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir plus entecavir combination
Description: continuing tenofovir plus entecavir
Study: NCT03904940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Contact Insole
Description: Ethyl vinyl acetate insole shaped in the cast of the patient's foot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ethyl vinyl acetate flat insole
Description: Flat insole made of the same material ethyl vinyl acetate